GLP-1s + Peptides Are Changing Fast, Here’s What You Need To Know

Eli Lilly released tirzepatide (Zepbound) in single-dose vial form in September 2024.

"in September of 2024, uh Eli Lilly released Zepbound, which is tirzepatide in a vial form." (said at 0:17:34)

No published record matching the claim regarding Eli Lilly's commercial release of Zepbound (tirzepatide) in vial form in September 2024 was located in the indexed biomedical literature; this does not prove the claim false.

In September 2023, the FDA placed several compounded peptides (such as BPC-157) onto the Category 2 bulk drug substances list, restricting compounding pharmacies from compounding them due to safety concerns.

"So, in September of 2023, we all woke up to the reality that the FDA had pulled all of these different peptides that we had been able to compound and have access to our patients for gosh, 10 years... What happened to them? They went onto what's called a Category 2 list." (said at 0:22:45)

No published literature or PubMed-indexed record matching the specific claim regarding the FDA's September 2023 placement of BPC-157 or other peptides onto the Category 2 bulk drug substances list was located; this does not prove the claim false. While published narrative reviews discuss BPC-157 as a synthetic pentadecapeptide with preclinical regenerative properties and notable regulatory barriers to clinical development (PMID: 42198317, PMID: 40789979), and studies address the general framework of 503B compounding facilities and state-level peptide access (PMID: 42394939), none of the retrieved biomedical literature documents the specific September 2023 regulatory action or Category 2 classification mentioned by the host.

• context: Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. (Current reviews in musculoskeletal medicine 2025) · cited 19x in the literature

  "Despite its growing popularity among athletes and its wide availability through non-regulated sources, there is minimal human data available. Until well-designed clinical trials are conducted, BPC-157 should be considered investigational, and its use approached with caution." (abstract, recent findings, passage verified)

  pubmedfull study (doi)
• context: BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulati… (Pharmaceutics 2026) · cited 2x in the literature

  "BPC-157 (body protection compound 157) is a synthetic pentadecapeptide derived from a gastric protein fragment with reported cytoprotective and regenerative properties across multiple organ systems... Despite over three decades of preclinical research demonstrating consistent biological activity, its pharmaceutical development remains rudimentary, with no approved formulation, no validated dosing regimen, and no completed Phase II clinical trial." (abstract, background/objectives)

  pubmedfull study (doi)

Evidence-based medicine is formally defined as a three-part model integrating scientific evidence, physician clinical experience, and patient preferences/lived experience.

"the definition of evidence-based medicine is only reliant upon studies because that's not what evidence-based medicine—that's not the definition. The definition is a three-pronged approach. It's like a three-pronged stool, you guys, and it is equally as important as the physician's experience, and then the patient's desires and lived experience with the treatment." (said at 0:42:07)

No published record matching the claim that evidence-based medicine is formally defined as a three-part model integrating research evidence, clinical expertise, and patient preferences was located; this does not prove the claim false.